Cargando…

PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors

Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimitrakopoulos, Foteinos-Ioannis, Nikolakopoulos, Achilleas, Kottorou, Anastasia, Kalofonou, Fotini, Liolis, Elias, Frantzi, Theodora, Pyrousis, Ioannis, Koutras, Angelos, Makatsoris, Thomas, Kalofonos, Haralabos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280986/
https://www.ncbi.nlm.nih.gov/pubmed/32429368
http://dx.doi.org/10.3390/cancers12051257
_version_ 1783543826029215744
author Dimitrakopoulos, Foteinos-Ioannis
Nikolakopoulos, Achilleas
Kottorou, Anastasia
Kalofonou, Fotini
Liolis, Elias
Frantzi, Theodora
Pyrousis, Ioannis
Koutras, Angelos
Makatsoris, Thomas
Kalofonos, Haralabos
author_facet Dimitrakopoulos, Foteinos-Ioannis
Nikolakopoulos, Achilleas
Kottorou, Anastasia
Kalofonou, Fotini
Liolis, Elias
Frantzi, Theodora
Pyrousis, Ioannis
Koutras, Angelos
Makatsoris, Thomas
Kalofonos, Haralabos
author_sort Dimitrakopoulos, Foteinos-Ioannis
collection PubMed
description Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline clinical characteristics of aNSCLC patients, in the form of a scoring system, and to investigate its predictive and prognostic value in NSCLC patients treated with ICIs. A total of 112 patients with advanced (stages IIIA to IV) NSCLC, treated with nivolumab or pembrolizumab, were enrolled in this study. Patras Immunotherapy Score (PIOS) was developed based on four of the studied parameters (performance status (PS), body mass index (BMI), age, and lines of treatment (LOT), which were incorporated into our formula (PS × BMI/ LOT × age). PIOS score was strongly associated with best overall responses (BOR), with those patients having benefit/good response (stable disease (SD) or partial (PR) or complete response (CR), achieving a higher score compared to patients who developed progressive disease (PD) (p < 0.001). Furthermore, PIOS score was associated with progression-free survival (PFS), since high-score patients had longer PFS (p < 0.001, hazard ratio (HR) = 0.469). Moreover, PIOS was associated with post-immunotherapy overall survival (OS), with high-score patients having improved OS (log-rank p = 0.019). This study suggests that a combination of baseline parameters, which give rise to PIOS score, may predict the best response of NSCLC patients treated with anti-program cell death -1 (PD-1) monotherapy as well as it may have a potent prognostic value for PFS and post immunotherapy OS.
format Online
Article
Text
id pubmed-7280986
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72809862020-06-15 PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors Dimitrakopoulos, Foteinos-Ioannis Nikolakopoulos, Achilleas Kottorou, Anastasia Kalofonou, Fotini Liolis, Elias Frantzi, Theodora Pyrousis, Ioannis Koutras, Angelos Makatsoris, Thomas Kalofonos, Haralabos Cancers (Basel) Article Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline clinical characteristics of aNSCLC patients, in the form of a scoring system, and to investigate its predictive and prognostic value in NSCLC patients treated with ICIs. A total of 112 patients with advanced (stages IIIA to IV) NSCLC, treated with nivolumab or pembrolizumab, were enrolled in this study. Patras Immunotherapy Score (PIOS) was developed based on four of the studied parameters (performance status (PS), body mass index (BMI), age, and lines of treatment (LOT), which were incorporated into our formula (PS × BMI/ LOT × age). PIOS score was strongly associated with best overall responses (BOR), with those patients having benefit/good response (stable disease (SD) or partial (PR) or complete response (CR), achieving a higher score compared to patients who developed progressive disease (PD) (p < 0.001). Furthermore, PIOS score was associated with progression-free survival (PFS), since high-score patients had longer PFS (p < 0.001, hazard ratio (HR) = 0.469). Moreover, PIOS was associated with post-immunotherapy overall survival (OS), with high-score patients having improved OS (log-rank p = 0.019). This study suggests that a combination of baseline parameters, which give rise to PIOS score, may predict the best response of NSCLC patients treated with anti-program cell death -1 (PD-1) monotherapy as well as it may have a potent prognostic value for PFS and post immunotherapy OS. MDPI 2020-05-16 /pmc/articles/PMC7280986/ /pubmed/32429368 http://dx.doi.org/10.3390/cancers12051257 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dimitrakopoulos, Foteinos-Ioannis
Nikolakopoulos, Achilleas
Kottorou, Anastasia
Kalofonou, Fotini
Liolis, Elias
Frantzi, Theodora
Pyrousis, Ioannis
Koutras, Angelos
Makatsoris, Thomas
Kalofonos, Haralabos
PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
title PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
title_full PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
title_fullStr PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
title_full_unstemmed PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
title_short PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
title_sort pios (patras immunotherapy score) score is associated with best overall response, progression-free survival, and post-immunotherapy overall survival in patients with advanced non-small-cell lung cancer (nsclc) treated with anti-program cell death-1 (pd-1) inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280986/
https://www.ncbi.nlm.nih.gov/pubmed/32429368
http://dx.doi.org/10.3390/cancers12051257
work_keys_str_mv AT dimitrakopoulosfoteinosioannis piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors
AT nikolakopoulosachilleas piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors
AT kottorouanastasia piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors
AT kalofonoufotini piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors
AT lioliselias piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors
AT frantzitheodora piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors
AT pyrousisioannis piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors
AT koutrasangelos piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors
AT makatsoristhomas piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors
AT kalofonosharalabos piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors